Recombinant human Angiotensin Converting Enzyme 2 (ACE2) therapy targets imbalances of the Renin Angiotensin System (RAS) which play an important negative role in various pathologic conditions such as respiratory, cardiovascular, renal and hepatic diseases. GSK presently pursues APN01 clinically in ARDS (acute respiratory distress syndrome) and PAH (pulmonary arterial hypertension).